Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
5(71.4%)
N/A
2(28.6%)
7Total
Phase 2(5)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT07409844Phase 2Not Yet Recruiting

Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer

Role: lead

NCT05740137Not ApplicableCompleted

Adenoma Detection Rate in Artificial Intelligence-assisted Colonoscopy

Role: lead

NCT05609656Phase 2Terminated

Electroporation and Immunotherapy in Metastatic Colorectal Cancer

Role: lead

NCT05754229Not ApplicableActive Not Recruiting

Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy

Role: lead

NCT05435053Phase 2Terminated

Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer

Role: lead

NCT05042700Phase 2Unknown

The Effect of Melatonin in Patients With Low Anterior Resection Syndrome

Role: lead

NCT05740969Phase 2Unknown

Gene and Protein Expression Profiles After Treatment of Actinic Keratoses

Role: lead

All 7 trials loaded